News

Read our latest news.

  • April 6, 2022

BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status

More
  • March 15, 2022

BostonGene and Thomas Jefferson University Announce Publication in Clinical Cancer Research Predicting Immunotherapy Response for Patients with Head and Neck Cancer

More
  • February 22, 2022

BostonGene Earns Recognition from Cancer Cell for its State-of-the-Art Technology in Cancer Research and Oncology

More
  • February 8, 2022

BostonGene Expands Testing Capabilities to Predict Patient Response to Immunotherapy

More
  • January 11, 2022

BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer

More
  • December 14, 2021

BostonGene and NEC Announce Global Partnership

More
  • December 6, 2021

BostonGene Announces Three Oral and Four Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition

More
  • November 30, 2021

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

More
  • November 2, 2021

BostonGene Announces Publication in Cancer Research

More